Search Results

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that members of management will participate in the following upcoming investor conferences.

Avadel Pharmaceuticals plc announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024.

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, provided a corporate update and announced its financial results for the quarter ended March 31, 2024.

Avadel Pharmaceuticals plc announced today that members of management will participate in the following upcoming investor conferences.

Avadel Pharmaceuticals plc announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET.

Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2024.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston.

The FDA has three regulatory milestones in the next two weeks, including a decision on a subcutaneous formulation of an effective multiple sclerosis therapy.